Ranbaxy restarts generic Lipitor production; More Avandia suits filed; Genentech tax adjustment put hurt on Oregon town;

@FiercePharma: Sanofi's new 6-in-1 vaccine won backing from Europe's CHMP. Would compete with $GSK's Infanrix Hexa. News | Follow @FiercePharma

@EricPFierce: Elan CEO Martin gives shareholders a taste of honey. More | Follow @EricPFierce

@AlisonBFierce: The flu vaccine was effective in only 56% of those who received it, largely failing to protect against the elderly. More | Follow @AlisonBFierce

> Ranbaxy is resuming production of generic Lipitor, which it halted after the recall of some lots because they might have been tainted by ground glass. Story

> Kentucky has filed suit against GlaxoSmithKline ($GSK), accusing it of some of the same kinds of indiscretions with Avandia which figured into its $3 billion settlement last year with the feds. News

> Florida has joined the states looking at legislating limits on biosimilars. More

> Some insurers are raising questions about the $235,000 cost of Juxtapid, a treatment for people with extremely high cholesterol who currently have to have their blood filtered. Story

> Roche ($RHHBY) subsidiary Genentech expects to fill nearly 600 new positions this year, many at their South San Francisco headquarters. Item

Medical Device News

 @FierceMedDev: Abbott chops 200 jobs at Ireland plant. Story | Follow @FierceMedDev

 @MarkHFierce: A cancer diagnostic test you could use yourself in the bathroom at home? It's coming... More | Follow @MarkHFierce

 @DamianFierce: Despite a revenue jump, Volcano's profits tanked in Q4. News | Follow @DamianFierce

> J&J's DePuy recalls knee component over risk of limb loss. Story

> Stryker sued over metal-hip safety shortfalls. Item

> Abiomed gets out from under FDA's Impella warning letter. Report

Biotech News

 @FierceBiotech: FDA approved T-DM1 for patients with HER2-positive breast cancer. Story | Follow @FierceBiotech

@JohnCFierce: Elan lines up biotech deals as it preps for $3B Tysabri windfall. Report | Follow @JohnCFierce

> India probes cause of 436 clinical trial deaths. Item

> J&J stakes out Boston/Cambridge HQ for new innovation center. Report

> Report: Booming Genentech plans 600 new hires in 2013. News

> Upstart Blaze banks $8.5M A round for new cancer surgery tech. Article

And finally... The $162.6 million reduction in the assessed valuation of a Genentech facility in Hillsboro, OR, has put a world of hurt on that town's municipal budget. Story

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.